Evidence map›Paper›PMID 40971628›Full record

ReviewThe British journal of radiology2025

Circulating tumour cells for the prediction of the response to radiation therapy in prostate cancer.

Camille Landry, Daria Klusa, Denis Cochonneau, Stéphane Supiot, Dominique Heymann

Abstract readReview
In one paragraph

Review in The British journal of radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Camille LandryDepartment of Radiation Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, 44805, France.
Daria KlusaTumour Heterogeneity and Precision Medicine" Laboratory, Institut de Cancérologie de l'Ouest, Saint-Herblain, 44805, France.
Denis CochonneauTumour Heterogeneity and Precision Medicine" Laboratory, Institut de Cancérologie de l'Ouest, Saint-Herblain, 44805, France.
Stéphane SupiotDepartment of Radiation Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, 44805, France.ORCID 0000-0003-2094-1708
Dominique HeymannTumour Heterogeneity and Precision Medicine" Laboratory, Institut de Cancérologie de l'Ouest, Saint-Herblain, 44805, France.ORCID 0000-0001-7777-0669

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating tumour cells (CTCs) have emerged as a promising biomarker for assessing prognosis and predicting therapeutic efficacy in various cancers, including metastatic prostate cancer. However, predicting patient response to treatment, including radiation therapy (RT), remains a significant clinical challenge. This review explores the value of CTCs as prognostic markers in RT for prostate cancer, discussing their detection methods, biological significance, clinical relevance, and future implications.

Indexed as

Neoplastic Cells, CirculatingProstatic NeoplasmsBiomarkers, TumorHumansMalePrognosisTreatment OutcomeBiomarkers, Tumorcirculating tumour cellsprostate cancerradiotherapy

Identifiers

PMID40971628
PMCPMC12659748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.